Partnering with innovative technologies on next-generation sequencing data analysis
Our team is absolutely convinced that collaborating is a central strategic cornerstone to expand our business and drive our innovation. We highly welcome opportunities to work with academia and industry on new applications of next-generation sequencing (NGS) data analysis, novel products based on NGS as well as to cooperate in distribution partnerships.
The main goal of BIOSTAR17 consortium is to develop the world’s first reliable and robust EML4-ALK fusion protein biosensor as companion diagnostic (CD), which works with patient`s blood samples, for anti-ALK therapy in late stage EML4-ALK translocation positive non-small-cell lung carcinoma (NSCLC) patients. The product will be a chip-based fluorescent detection sensor working in a sandwich format employing aptamers asdetection reagents. AptaIT will perform analysis of next-generation sequencing data in combination with high throughput interaction analysis for the identification of aptamers from SELEX and their subsequent optimization in terms of affinity, specificity and reduced molecular size. BIOSTAR is a consortium of highly complementary partners from South Korea, Canada and Germany.
The BIOSTAR project was approved by the European program Eurostars and is co-funded by EUREKA member countries and the European Union.
- AptaIT GmbH, Germany
- ASAN Medical Center, South Korea
- Fraunhofer-Institut für Keramische Technologien und Systeme IKTS, Germany
- InnoPharmaScreen Inc., South Korea (Project Coordinator)
- NeoVentures Biotechnology Inc., Canada
APERIM , which stands for ‘Advanced bioinformatics platform for Personalized cancer IMmunotherapy’, will develop an innovative bioinformatics platform that aims to accelerate the clinical translation and maximize the accessibility and utility of biomedical data in research and medicine. Technological advances in next-generation sequencing and data analysis allow for the first time the development of personalized cancer immunotherapies, which target patient specific mutations. APERIM addresses specific bottlenecks in bioinformatics that currently hamper the clinical application. The APERIM team is a transdisciplinary network of leading experts in bioinformatics and cancer immunology. Partners will develop user-friendly sequence analysis software modules as well as analytical SOPs for clinical use, and apply the bioinformatics platform in clinical settings.
APERIM has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 633592.
- AptaIT GmbH, Germany
- Cemit GmbH, Austria (Project Management)
- Definiens AG, Germany
- Eberhard Karls Universität Tübingen, Germany
- Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III, Spain
- Institut National de la Sante et de la Recherche Medicale (INSERM), France
- Masarykova Univerzita, Czech Republic
- Medizinische Universität Innsbruck, Austria (Project Coordinator)
- Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis(NKI-AVL), Netherlands
- TRON GmbH, Germany
- Universiteit Utrecht, Netherlands
Aptagen, LLC is a biotechnology company offering aptamer (oligo antibody) products and services as research reagents, diagnostic and biomarker discovery tools, as well as for use in drug discovery and targeted delivery for therapeutics, and bioindustrial applications. Aptagen and AptaIT are partners for SELEX sequencing and NGS data analysis.
AptaIT and TRON cooperate in the field of next-generation sequencing (NGS). TRON-Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz gGmbH is a biopharmaceutical research organization that pursues new diagnostics and drugs for the treatment of cancer and other severe diseases with high medical need. A focus of TRON is the development of novel platforms for individualized therapies and biomarkers, translating basic research into drug applications. TRON partners with academic institutions, biotech companies and the pharmaceutical industry, executing research with leading-edge technologies and supporting the development of innovative drugs to promote human health.
2bind GmbH is a service provider in the field of biophysical analyses of molecular interactions. 2bind possesses expert knowledge in the innovative MicroScale Thermophoresis (MST) technology, which is used to determine binding affinities and stoichiometries of any kind of interaction in solution.
AbCheck s.r.o is an antibody company, offering the discovery of therapeutic antibodies for partner companies from proprietary human antibody libraries as well as from immunized animals. The technology platform is complemented by a high capacity solution for humanization and optimization of affinities as well as developability-related properties. AbCheck is a fully owned subsidiary of Affimed Therapeutics GmbH. AbCheck and AptaIT cooperate on antibody discovery and NGS data analysis.
Please do not hesitate to contact us, if you have a suggestion regarding next-generation sequencing analysis or sequence analysis software for a research consortium or for a co-marketing or distribution partnership.